Table 1. JAK2- mutant CHIP relative... | American Society of Hematology

Table 1.

JAK2-mutant CHIP relative incident risk of VTE and prevalence in the general population compared with heterozygous factor V Leiden and heterozygous prothrombin gene mutation G20210A in the UK Biobank

Thrombophilia	HR of first episode of VTE compared with controls	Prevalence in the population
Heterozygous factor V Leiden	2.36 (95% CI, 2.21-2.52)	4.4%
Heterozygous prothrombin G20210A	1.91 (95% CI, 1.74-2.10)	2.3%
JAK2 CHIP	6.24 (95% CI, 2.8-13.9)	98/430 000 (0.02%) 0.14%-3% in other studies¹¹^,^32-34
Non-JAK2 CHIP	1.15 (95% CI, 1.04-1.28)	14 417/430 000 (3.4%)

Thrombophilia	HR of first episode of VTE compared with controls	Prevalence in the population
Heterozygous factor V Leiden	2.36 (95% CI, 2.21-2.52)	4.4%
Heterozygous prothrombin G20210A	1.91 (95% CI, 1.74-2.10)	2.3%
JAK2 CHIP	6.24 (95% CI, 2.8-13.9)	98/430 000 (0.02%) 0.14%-3% in other studies¹¹^,^32-34
Non-JAK2 CHIP	1.15 (95% CI, 1.04-1.28)	14 417/430 000 (3.4%)